Acute myeloid leukemia trials in Canada

In Canada 23 Also abroad 761

23 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Where
Calgary, Edmonton, Greenfield Park, Halifax, Montreal, Ottawa, Toronto, Winnipeg
Age
18 years to 59 years
People
335 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT05554406
Phase 2Taking people
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Where
Montreal
Age
18 years and over
People
147 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06317649
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Calgary, Halifax, Hamilton, London, Montreal, Toronto, Vancouver, Winnipeg
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 2Taking people
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Where
Calgary, Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Ottawa, Toronto, Winnipeg
Age
18 years and over
People
2,000 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT05564390
Phase 2Taking people
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Where
Calgary, Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Toronto, Winnipeg
Age
18 years to 59 years
People
153 worldwide
Run by
National Cancer Institute (NCI)
See details and how to joinNCT05554393
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Montreal, Toronto
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
London, Montreal, Toronto
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Montreal, Vancouver
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Toronto
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1Taking people
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Where
Toronto
Age
0 years to 21 years
People
20 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT06376162 · EU 2023-505262-28-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
St. John's, Toronto
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 2Not yet taking people in Canada
Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia
Where
Vancouver
Age
18 years and over
People
20
Run by
Florian Kuchenbauer
See details and how to joinNCT07755202
Phase 3Taking people
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Where
Calgary, Edmonton, Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
6 months to 21 years
People
1,400 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT04293562
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Edmonton, Toronto
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Where
Calgary, Edmonton, Halifax, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
Age
Up to 22 years
People
960 worldwide
Run by
PedAL BCU, LLC
See details and how to joinNCT04726241
No phaseTaking people
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
Where
London
Age
6 years to 39 years
People
330 worldwide
Run by
Children's Oncology Group
See details and how to joinNCT05702645
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Edmonton, Nova Scotia, Ottawa, Toronto
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 2Not yet taking people in Canada
Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)
Where
Winnipeg
Age
18 years and over
People
75
Run by
University of Manitoba
See details and how to joinNCT07528417
Phase 2Taking people
Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Where
Winnipeg
Age
18 years and over
People
75
Run by
University of Manitoba
See details and how to joinNCT06599762
Phase 1Not yet taking people in Canada
Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma
Where
Montreal, Toronto
Age
2 years to 12 years
People
12
Run by
Michel Duval
See details and how to joinNCT07518654
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Calgary, Edmonton
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
No phaseTaking people
Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy
Where
Toronto
People
45
Run by
University Health Network, Toronto
See details and how to joinNCT06510868
Phase 1Taking people
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Where
Toronto
Age
18 years and over
People
242 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT04260022